RNA fusion lung cancer research panel, 4/15

April 2015—Thermo Fisher Scientific has released a next-generation sequencing RNA panel and workflow that enables targeted sequencing of fusion transcripts for clinical research. The Ion Torrent AmpliSeq RNA Fusion Lung Cancer Research Panel allows simultaneous sequencing of 70 ALK, RET, ROS1, and NTRK1 fusion transcripts associated with lung cancer as well as 5’ and 3’ ALK gene expression. The panel was verified by leading clinical researchers from the OncoNetwork Consortium, which comprises 12 translational cancer research institutes.

Based on Ion Torrent AmpliSeq technology, the NGS fusion detection workflow was designed for ease of use and high performance using as little as 10 ng of FFPE-derived RNA. The panel can be used in conjunction with the Ion Torrent AmpliSeq Colon and Lung Cancer Research Panel v2 to obtain a complete view of mutations from lung tissue FFPE samples and fine-needle aspirates.

Integrated with Ion Reporter Software, the application includes easy-to-use fusion reporting and visualization tools for fusion classification.

Thermo Fisher Scientific *, 760-603-7200*